Tech Company Financing Transactions
Modus Therapeutics Funding Round
Rosetta Partners and private investors participated in a $3.6 million funding round for Modus Therapeutics. The round was announced on 2/23/2017.
Transaction Overview
Company Name
Announced On
2/23/2017
Transaction Type
Venture Equity
Amount
$3,566,252
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Sankt Eriksgatan 117
Stockholm, SE-113 43
Sweden
Stockholm, SE-113 43
Sweden
Phone
Website
Email Address
Overview
Modus Therapeutics is a Swedish drug development company developing sevuparin -- a novel drug to treat people suffering from Sickle Cell Disease -- a painful, inherited blood disorder affecting millions of people around the globe.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ellen Donnelly
Chief Scientific Officer
Mats Wahlgren
Browse more venture capital transactions:
Prev: 2/23/2017: Tala venture capital transaction
Next: 2/23/2017: Roadmunk venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document every notable VC transaction. VC transactions reported here come from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs